Myeloma XII

Trial description
A phase III study to determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stem
Contact name
Dr Charles Crawley
Trial start date
Monday, May 22, 2017
Trial end date
Friday, December 31, 2021
Trial tumour type
Show on Radiotherapy